Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome

Experimental Neurology

Volumn 183, Issue 1, 2003, Pages 56-65

  Hill, Joanna M ^a   Ades, Anne M ^b   McCune, Susan K ^b   Sahir, Nadia ^a   Moody, Elizabeth M ^a   Abebe, Daniel T ^a   Crnic, Linda S ^c   Brenneman, Douglas E ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Down syndrome; GTP insensitive binding; Immunocytochemistry; Ts65Dn segmental trisomy; Vasoactive intestinal peptide; VIP binding sites; VIP mRNA

Indexed keywords

MESSENGER RNA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN SYNDROME; FEMALE; HIPPOCAMPUS; IN SITU HYBRIDIZATION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PUTAMEN; RAPHE NUCLEUS; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; TRISOMY 21; VESTIBULAR NUCLEUS; WILD TYPE;

EID: 0042190136     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00164-X     Document Type: Article

References (62)

1. Bambrick L.L., Golovine V.A., Blaustein M.P., Yarowsky P.J., Krueger B.K. Abnormal calcium homeostasis in astrocytes from the trisomy 16 mouse. Glia. 10:1997;352-358.
2. Belichenko P.V., Salehi A., Delcroix J.-D., Cooper J., Mobley W.C. Neuronal and synaptic alteration in the partial trisomy mice. Soc. Neurosci. Abstr. 26:2000;1543.
3. Belichenko P.V., Masliah E., Kleschenikiv A., Mobley W.C. Synaptic alterations in the partial trisomy 16 mice. Soc. Neurosci. Abst. 27:2001;880.11.
4. Bowes C., Li T., Frankel W.N., Dancigar M., Coffin J.M., Applebury M.L., Farber D.B. Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase. Proc. Natl. Acad. Sci. USA. 90:1993;2955-2959.
5. Brenneman D.E., Hauser J., Mokolla M., Hill J.M., Ring M., Crnic L.S., Phillips T.M. VIP-mediated regulation of chemokine, cytokine and growth factor release from glial cultures derived from a mouse model of mental retardation. Regul. Pept. 102:2001;51.
6. Brenneman D.E., Neale E.A., Foster G.A., d'Autrement S., Westbrook G.L. Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J. Cell Biol. 104:1987;1603-1610.
7. Brenneman D.E., Gozes I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97:1996;2299-2307.
8. Brenneman D.E., Hauser J., Spong C.Y., Phillips T.M., Pert C.B., Ruff M. VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. Brain Res. 838:1999;27-36.
9. Brenneman D.E., Hill J.M., Glazner G.W., Gozes I., Phillips T.W. Interleukin-1 alpha and vasoactive intestinal peptide enigmatic regulation of neuronal survival . Int. J. Dev. Neurosci. 13:1995;187-200.
10. Brenneman D.E., Nicol T., Warren D., Bowers L.M. Vasoactive intestinal peptide a neurotrophic releasing agent and an astroglial mitogen . J. Neurosci. Res. 25:1990;386-394.
11. Caserta M.T. Neuropeptide-Y immunoreactive neurons in murine trisomy-16 cortical cultures plasticity of expression and differentiation. Mol. Chem. Neuropathol. 22:1994;197-210.
12. Chrome R., Cowie V., Slater E. A statistical note on cerebellar and brain stem weight in Down syndrome. J. Ment. Defic. Res. 10:1966;69-72.
13. Cooper J.D., Salehi A., Delcroix J.-D., Howe C.L., Belichenko P.V., Chua-Couzens J., Kilbridge J.F., Carlson E.J., Epstein C.J., Mobley W.C. Failed retograde transport of NGF in a mouse model of Down's syndrome Reversal of cholinergic neurodegenerative phenotype following NGF infusion . Proc. Natl. Acad. Sci. USA. 98:2001;10439-10444.
14. Corsi P., Forloni G., Troia M., Lettini T., Coyle J.T. Somatostatin expression in Ts16 mouse brain cultures. J. Mol. Neurosci. 10:1998;99-111.
15. Coyle J.T., Oster-Granite M.L., Gearhart J.D. The neurobiologic consequences of Down syndrome. Brain Res. Bull. 16:1986;773-787.
16. Festoff B.E., Nelson P.G., Brenneman D.E. Prevention of activity-dependent neuronal death vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting, neurotrophic serpin, protease nexin 1 . J. Neurobiol. 30:1996;255-266.
17. Gerhold L.M., Horvath T.L., Freeman M.E. Vasoactive intestinal peptide fibers innervate neuroendocrine dopaminergic neurons. Brain Res. 919:2001;48-56.
18. Giladi E., Shani Y., Gozes I. The complete structure of the rat VIP gene. Mol. Brain Res. 7:1990;261-267.
19. Glowa J.R., Panlilio L.V., Brenneman D.E., Gozes I., Hill J.M. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570:1992;49-53.
20. Granholm A.E., Sanders L.A., Crnic L.S. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. 161:2000;647-663.
21. Gressens P., Hill J.M., Gozes I., Fridkin M., Brenneman D.E. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature. 362:1993;155-158.
22. Gressens P., Hill J.M., Paindaveine B., Gozes I., Fridkin M., Brenneman D.E. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94:1994;2020-2027.
23. Davisson M.T., Bechtel L.J., Akeson E.C., Fortna A., Slavov D., Gardiner K. Evolutionary breakpoints on human chromosome 21. Genomics. 78:2001;99-106.
24. Davisson M.T., Schmidt C., Akeson E.C. Segmental trisomy of murine chromosome 16 a new model system for studying Down syndrome . Prog. Clin. Biol. Res. 360:1990;263-280.
25. Davisson M.T., Schmidt C., Akeson E.C. Segmental trisomy as a mouse model for Down's syndrome. Prog. Clin. Biol. Res. 384:1993;117-133.
26. Demas G.E., Nelson R.J., Krueger B.K., Yarowsky P.J. Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behav. Brain Res. 90:1998;199-201.
27. Dierssen M., Vallina I.F., Baamonde C., Lumbreras M.A., Martinez-Cue C., Calatayud S.G., Florez J. Impaired cyclic AMP production in the hippocampus of a Down syndrome murine model. Dev. Brain Res. 95:1996;122-124.
28. Dierssen M., Vallina I.F., Baamonde C., Garcie-Calatayud S., Lumbreras M.A., Florez J. Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. Brain Res. 749:1997;238-244.
29. Epstein C. J. Down syndrome (trisomy 21). Shriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic Basis of Inherited Disease. 1989;291-326 McGraw-Hill, New York.
30. Escorihuela R.M., Fernandez-Teruel A., Vallina I.F., Baamonde C., Lumbreras M.A., Dierssen M., Tobena A., Florez J. A behavioral assessment of Ts65Dn mice a putative Down syndrome model . Neurosci. Lett. 199:1995;143-146.
31. Griffin W.S.T., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 86:1989;7611-7615.
32. Hill J.M., Agoston D.V., Gressens P., McCune S.K. Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain relation to ontogenic events . J. Comp. Neurol. 342:1994;186-205.
33. Hill J.M., Gozes I., Hill J.L., Fridkin M., Brenneman D.E. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides. 12:1991;187-192.
34. Hill J.M., Harris A., Hilton-Clarke D.I. Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain. Neuroscience. 48:1992;925-932.
35. Hill J.M., Mervis R.F., Politi J., McCune S.K., Gozes I., Fridkin M., Brenneman D.E. Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann. N.Y. Acad. Sci. 739:1994;211-225.
36. Hill J.M., Lee S.J., Dibbern D.A., Fridkin M., Gozes I., Brenneman D.E. Pharmacologically distinct vasoactive intestinal peptide binding sites CNS localization and role in embryonic growth . Neuroscience. 93:1999;783-791.
37. Hill J.M., McCune S.K., Alvero R.J., Glazner G.W., Henins K.A., Stanziale S.F., Keimowitz J.R., Brenneman D.E. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J. Clin. Invest. 97:1996;202-208.
38. Hill J.M., Mehnert J., McCune S.K., Brenneman D.E. Vasoactive intestinal peptide regulation of nerve growth factor in the embryonic mouse. Peptides. 23:2002;1803-1808.
39. Holtzman D.M., Kilbridge J., Chen K.S., Rabin R., Luche R., Carlson E., Epstien C.J., Mobley W.C. Preliminary characterization of the central nervous system in partial trisomy 16 mice. Epstein C.J., Hassold T., Lott I.T., Nadel L., Paterson D. Etiology and Pathogenesis of Down Syndrome. 1995;227-240 Wiley-Liss, New York.
40. Holtzman D.M., Santucci D., Kilbridge J., Chuacouzens J., Fontana D.H., Daniels S.E., Johnson R.N., Chen K., Sun Y.L., Carlson E., Alleva E., Epstein C.J., Mobley W.C. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. USA. 93:1996;13333-13338.
41. Hook, E.B., 1981. Down Syndrome: It's Frequency in Human Populations and Some Factors Pertinent to Variation in Rates, in: Cruz, F.F.D.l., Gerald, P.S. (Eds.), Trisomy 21 (Down Syndrome): Research Perspectives, University Park Press, Baltimore, MD, pp. 3-68.
42. Karacay B., O'Dorisio M.S., Kasow K., Hollenback C., Krahe R. Expression and fine mapping of murine vasoactive intestinal peptide receptor 1. J. Mol. Neurosci. 17:2001;311-324.
43. Korenberg J.R., Chen X.N., Devon K.L., Noya D., Oster-Granite M.L., Birren B.W. Mouse molecular cytogenetic resource 157 BACs link the chromosomal and genetic maps . Genome Res. 9:1999;514-523.
44. Magistretti P.J., Morrison J.H. Noradrenaline-containing and vasoactive intestinal peptide-containing neuronal systems in neocortex - Functional convergence with contrasting morphology. Neuroscience. 24:1988;367-387.
45. Nelson P.G., Fitzgerald S., Rapoport S.I., Neale E.A., Galdzicki Z., Dunlap V., Bowers L., Agoston D.v. Cerebral cortical astroglia from the trisomy 16 mouse, a model for Down syndrome, produce neuronal cholinergic deficits in cell culture. Proc. Natl. Acad. Sci. USA. 94:1997;12644-12648.
46. Nelson K.B., Grether J.K., Croen L.A., Dambrosia J.M., Dickens B.F., Jellife L.L., Hansen R.L., Phillips T.M. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann. Neurol. 49:2001;597-606.
47. Oster-Granite M.L., Gearhart J.D., Reeves R.H. Neurobiological consequences of Trisomy 16 in mice. Epstein C.J. The Neurobiology of Down syndrome. 1986;137-151 Raven Press, New York.
48. Pineau N., Lelievre V., Goursaud S., Hilairet S., Waschek J.A., Janet T., Muller J.-M. The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes. Neuropeptides. 35:2001;117-126.
49. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., Schmidt C., Bronson R.T., Davisson M.T. A mouse model for Down syndrome exhibits learning and behavior deficits. Nature Genet. 11:1995;177-184.
50. Richtsmeier J.T., Baxter L.L., Reeves R.H. Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice. Dev. Dyn. 17:2000;137-145.
51. Rumble B., Retalack R., Hilbich C., Simms G., Multhaup G., Martins R., Hockey A., Montgomery P., Beyreuther K., Masters C.L. Amyloid A4 protein and its precursors in Down's syndrome and Alzheimer's disease. N. Engl. J. Med. 320:1989;1446-1452.
52. Sago J., Carlson E.J., Smith D.J., Rubin E.M., Crnic L.S., Haung T.T., Epstein C.J. Genetic dissection of a region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatric Res. 48:2000;606-613.
53. Smith D.J., Stevens M.E., Sudanagunta S.P., Bronson R.T., Makhinson M., Watabe A.M., O'Dell T.J., Fung J., Weier H.U.G., Chengd J.F., Rubin E.M. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nature Genet. 16:1997;28-36.
54. Spong C.Y., Lee S.J., McCune S.K., Gibney G., Abebe D.T., Alvero R., Brenneman D.E., Hill J.M. Maternal regulation of embryonic growth the role of vasoactive intestinal peptide . Endocrinology. 140:1999;917-924.
55. Staiger J.F., Masanneck C., Bisler S., Zuschratter A., Zilles K. Excitatory and inhibitory neurons express c-fos in barrel-related columns after exploration of a novel environment. Neurosci. 109:2002;687-699.
56. Staiger J.F., Schubert D., Zuschratter W., Kotter R., Luhmann H.J., Zilles K. Innervation of interneurons immunoreactive for VIP by intrinsically bursting pyramidal cells and fast-spiking interneurons in infragranular layers of juvenile rat neocortex. Eur. J. Neurosci. 16:2002;11-20.
57. Strovel J., Stamberg J., Yarowsky P.J. Interphase FISH for rapid identification of a Down syndrome animal model. Cytogenet. Cell Genet. 86:1999;285-287.
58. Usdin T.B., Bonner T.I., Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 135:1994;2662-2680.
59. Weisnewski K.E., Weisnewski M.H., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:1985;278-282.
60. Wu J.W., Henins K.A., Gressens P., Gozes I., Fridkin M., Brenneman D.E., Hill J.M. Prenatal blockage of vasoactive intestinal peptide delays developmental milestones in the neonatal mouse. Peptides. 18:1997;1131-1137.
61. Young W.S. III, Mezey E., Siegel R.E. Vasopressin and oxytocin mRNAs in adrenalectomized and Brattleboro rats analysis by in situ hybridization histochemistry . Mol. Brain Res. 1:1986;231-241.
62. Zigmond R.E. LIF, NGF, and the cell body response to axotomy. Neuroscientist. 3:1997;176-185.